Results for tag: "Hemlibra"

Hemlibra (emicizumab-kxwh) is a hematological drug developed by Genentech, a member of the Roche Group, for the treatment of hemophilia A. It is a monoclonal antibody designed to replace the missing or defective factor VIII protein, which is necessary for normal blood clotting. Hemlibra is administered as a subcutaneous injection and is approved for both adults and children. It is the first drug of its kind to be approved for the prevention of bleeding episodes in hemophilia A patients without factor VIII inhibitors. Hemlibra is a part of a growing market of hematological drugs, which includes treatments for a variety of blood disorders, such as anemia, leukemia, and lymphoma. These drugs are used to treat a range of conditions, from mild to severe, and can be administered orally, intravenously, or subcutaneously. The companies in the Hemlibra market include Genentech, Novartis, Pfizer, Bayer, and Shire. Show Less Read more